ST 638

Drug Profile

ST 638

Latest Information Update: 03 Apr 2008

Price : $50

At a glance

  • Originator Kaneka
  • Developer Kanegafuchi Chemicals; Kaneka
  • Class Antihyperlipidaemics; Antineoplastics; Nootropics
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Atherosclerosis; Coronary artery restenosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Feb 2008 Discontinued for Coronary artery restenosis in Japan (unspecified route)
  • 11 Mar 1997 A study has been added to the Ischaemic Heart Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top